(2S)-1-(1,1-dioxo-1,2-thiazolidin-2-yl)-3,3-dimethylbutan-2-amine | 1132107-51-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (2S)-1-(1,1-dioxo-1,2-thiazolidin-2-yl)-3,3-dimethylbutan-2-amine
• CAS: 1132107-51-7
• 化学式: C₉H₂₀N₂O₂S
• 分子量: 220.336
• InChiKey: XHMFAQKXBFSBFV-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  光气 、 (2S)-1-(1,1-dioxo-1,2-thiazolidin-2-yl)-3,3-dimethylbutan-2-amine 在 碳酸氢钠 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 2-[(2S)-2-isocyanato-3,3-dimethylbutyl]-1,2-thiazolidine 1,1-dioxide
  参考文献：
  名称：

  Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings

  摘要：

  Extensive SAR studies of the P3 capping group led to the discovery of a series of potent inhibitors with sultam and cyclic sulfonyl urea moieties as the P3 capping. The bicyclic thiophene-sultam or phenyl- sultam cappings were selected for further SAR development. Modi. cation at the P3 side chain determined that the tert-butyl group was the best choice at that position. Optimization of P1 residue significantly improved potency and selectivity. The combination of optimal moieties at all positions led to the discovery of compound 33. This compound had the best overall pro. le in potency and PK profile: excellent K-i* of 5.3 nM and activity in replicon (EC90) of 80 nM, extremely high selectivity of 6100, and a good rat PO AUC of 1.43 mu Mh. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.111
• 作为产物：
  描述：

  tert-butyl N-[(2S)-1-(1,1-dioxo-1,2-thiazolidin-2-yl)-3,3-dimethylbutan-2-yl]carbamate 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 (2S)-1-(1,1-dioxo-1,2-thiazolidin-2-yl)-3,3-dimethylbutan-2-amine
  参考文献：
  名称：

  Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings

  摘要：

  Extensive SAR studies of the P3 capping group led to the discovery of a series of potent inhibitors with sultam and cyclic sulfonyl urea moieties as the P3 capping. The bicyclic thiophene-sultam or phenyl- sultam cappings were selected for further SAR development. Modi. cation at the P3 side chain determined that the tert-butyl group was the best choice at that position. Optimization of P1 residue significantly improved potency and selectivity. The combination of optimal moieties at all positions led to the discovery of compound 33. This compound had the best overall pro. le in potency and PK profile: excellent K-i* of 5.3 nM and activity in replicon (EC90) of 80 nM, extremely high selectivity of 6100, and a good rat PO AUC of 1.43 mu Mh. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.111

文献信息

• EP1730142B1
  申请人：——

  公开号：EP1730142B1

  公开（公告）日：2011-06-29
• Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus
  申请人：Chen X. Kevin

  公开号：US20070093430A1

  公开（公告）日：2007-04-26

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
• US7173057B2
  申请人：——

  公开号：US7173057B2

  公开（公告）日：2007-02-06
• US7619094B2
  申请人：——

  公开号：US7619094B2

  公开（公告）日：2009-11-17
• [EN] METHOD OF INHIBITING CATHEPSIN ACTIVITY<br/>[FR] PROCEDE D'INHIBITION DE L'ACTIVITE DE CATHEPSINE
  申请人：SCHERING CORP

  公开号：WO2006113942A2

  公开（公告）日：2006-10-26

  [EN] The present invention provides methods of inhibiting cathepsin activity in a subject in need thereof comprising administering to said subject an effective amount of at least one compound of various formulae (e.g., formula I-XXVI) disclosed herein. The present invention also provides methods of treatment of various diseases utilizing the foregoing compounds.
  [FR] L'invention concerne des procédés d'inhibition de l'activité de la cathepsine chez un sujet le nécessitant qui consiste à administrer à ce sujet une quantité efficace d'au moins un composé de diverses formules (par exemple, formule I-XXVI). Cette invention concerne également des procédés de traitement de diverses maladies au moyen des composés susmentionnés.